Evidence Europe Congress 2017
In-Person Event
Feb 22 - 23, 2017
London, England, GBOVERVIEW
Evidence Europe Congress 2017 is organized by Health Network Communications and would be held during Feb 22 - 23, 2017 at Park Plaza Victoria London, London, England, United Kingdom.
Evidence Europe is your opportunity to engage and sit alongside the pioneers who are driving forward effective health economics outcomes research and improving patient outcomes through big data.
The event will cover a range of different topics including :
• How to embrace digital technologies in outcomes research
• Application of RWE in clinical development
• Partnerships in RWE
• Can we achieve better clinical development for rare diseases?
• How to integrate payer expectations in early drug development
• How to interpret and use RWD
• Maximise future opportunities in RWE
• Comparing different approaches to data analysis and HTA in mature versus emerging markets
• Sustaining value and quality in healthcare
Prices :
2 Day Package : Group Booking : £1,075 - Book a group of 3+ before 02 December 2016 by saving £120 per person
3 Day Package: Group Booking : £1,525 - Book a group of 3+ before 02 December 2016 by saving £170 per person
Speakers : Peter Speyer, Global Head of Real World Evidence Solutions, Novartis, Dr Sarah Wamala Andersson, Principal Research Scientist, Real World Evidence, Medical Affairs, Northern European Cluster, Eli Lilly and Company, Jitendar Sharma, Head Healthcare Technology, Ministry Health and Family Welfare India, Alicia Granados, Head Global HTA Scientific Strategy, Sanofi Genzyme, Mogens Westergaard, Medical Evidence Director, AstraZeneca
Evidence Europe is your opportunity to engage and sit alongside the pioneers who are driving forward effective health economics outcomes research and improving patient outcomes through big data.
The event will cover a range of different topics including :
• How to embrace digital technologies in outcomes research
• Application of RWE in clinical development
• Partnerships in RWE
• Can we achieve better clinical development for rare diseases?
• How to integrate payer expectations in early drug development
• How to interpret and use RWD
• Maximise future opportunities in RWE
• Comparing different approaches to data analysis and HTA in mature versus emerging markets
• Sustaining value and quality in healthcare
Prices :
2 Day Package : Group Booking : £1,075 - Book a group of 3+ before 02 December 2016 by saving £120 per person
3 Day Package: Group Booking : £1,525 - Book a group of 3+ before 02 December 2016 by saving £170 per person
Speakers : Peter Speyer, Global Head of Real World Evidence Solutions, Novartis, Dr Sarah Wamala Andersson, Principal Research Scientist, Real World Evidence, Medical Affairs, Northern European Cluster, Eli Lilly and Company, Jitendar Sharma, Head Healthcare Technology, Ministry Health and Family Welfare India, Alicia Granados, Head Global HTA Scientific Strategy, Sanofi Genzyme, Mogens Westergaard, Medical Evidence Director, AstraZeneca
KEY DATES
22 Feb, 2017
Event Start Date
23 Feb, 2017
Event End Date
SPECIALITIES
Pharmacy and MedicineResearch and Clinical ResearchSUGGESTED HOTELS
CONFERENCE VENUE
Park Plaza Victoria LondonRELATED CONFERENCES & LIVE WEBINARS
Quick Links